Clinical Trial

Two Different Regiments of Pegmolesatide for Anemia in Patients With Chronic Kidney Disease Not Receiving Dialysis

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 27, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This was a multicenter, randomized, open label, non inferiority clinical study. It consisted of a 24-week treatment period (0-24 weeks) and a 24-week extension period (25-48 weeks). About 160 patients which had received Recombinant human erythropoietin (rHuEPO) or Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) treatment were randomized in a 1:1 ratio to receive Pegmolesatide with different administration regimens.
Trial Details
NCT Number NCT06946394
Lead Sponsor The First Affiliated Hospital of Dalian Medical University
Collaborators: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Renal Anemia in Non-dialysis Chronic Kidney Disease
Enrollment 160 participants
Start Date 2025-05
Primary Completion 2026-06 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-04-27